Lyell Immunopharma to Present at Goldman Sachs Healthcare Conference — Lyell Immunopharma, Inc.

Event summary

Lyell Immunopharma will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
A fireside chat with senior management is scheduled for 11:20 am Eastern Time.
The event will be webcast live and available for replay on Lyell’s investor relations page.
Lyell focuses on next-generation CAR T-cell therapies for cancer treatment.
LyFE manufacturing facility has capacity for over 1,200 CAR T-cell doses annually.

The big picture

Lyell Immunopharma’s participation in the Goldman Sachs Healthcare Conference underscores its push to engage with investors as it advances its pipeline of CAR T-cell therapies. The company is positioning itself in a rapidly evolving biotech landscape where cell therapies are gaining traction for both blood cancers and solid tumors. Lyell’s ability to scale its manufacturing capacity will be critical as it moves toward potential commercialization.

What we're watching

Clinical Progress: How Lyell’s next-generation CAR T-cell therapies will perform in late-stage trials and whether they can achieve durable clinical responses.
Manufacturing Scale: The pace at which Lyell can scale its LyFE manufacturing facility to meet potential commercial demand.
Market Positioning: Whether Lyell can differentiate itself in the competitive landscape of CAR T-cell therapies for both hematologic malignancies and solid tumors.